



## Nicox's Ordinary Shareholder Meeting

---

June 6, 2014.

Sophia Antipolis, France.

**Nicox S.A.** (NYSE Euronext Paris: COX) has convened an Ordinary shareholder meeting on a second call and on same agenda on **Wednesday June 18, 2014 at 2:00 pm CET** at the Hotel Mercure - rue Albert Caquot - 06560 Sophia Antipolis, the quorum was not reached on the first call on June 4, 2014.

The documents mentioned in articles L.225-115, R. 225-81 and R. 225-83 of the French *Code de commerce*, will be sent to shareholders upon written request. These documents are also available to shareholders at the headquarters and on the website of the Company ([www.nicox.com](http://www.nicox.com)).

---



### About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is latanoprostene bunod, a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit [www.nicox.com](http://www.nicox.com).

---

**This communication may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.**

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on April 2, 2014 and available on Nicox's website ([www.nicox.com](http://www.nicox.com)) and on the AMF's website ([www.amf-france.org](http://www.amf-france.org)).

---



**Contact:**

**Nicox Communications Corporate**

Tel +33 (0)4 97 24 53 00 | [communications@nicox.com](mailto:communications@nicox.com)